Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
36746088
DOI
10.1016/j.msard.2022.104477
PII: S2211-0348(22)00981-6
Knihovny.cz E-zdroje
- Klíčová slova
- Real-world evidence, Relapsing-remitting multiple sclerosis, Treatment outcome,
- MeSH
- dospělí MeSH
- fingolimod hydrochlorid MeSH
- imunologické faktory MeSH
- imunosupresiva MeSH
- lidé MeSH
- natalizumab MeSH
- recidiva MeSH
- relabující-remitující roztroušená skleróza * MeSH
- roztroušená skleróza * MeSH
- srovnávací výzkum účinnosti MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- fingolimod hydrochlorid MeSH
- imunologické faktory MeSH
- imunosupresiva MeSH
- natalizumab MeSH
BACKGROUND: Patients with relapsing-remitting multiple sclerosis (RRMS) who experience relapses on a first-line therapy (interferon, glatiramer acetate, dimethyl fumarate, or teriflunomide; collectively, "BRACETD") often switch to another therapy, including natalizumab or fingolimod. Here we compare the effectiveness of switching from a first-line therapy to natalizumab or fingolimod after ≥1 relapse. METHODS: Data collected prospectively in the MSBase Registry, a global, longitudinal, observational registry, were extracted on February 6, 2018. Included patients were adults with RRMS with ≥1 relapse on BRACETD therapy in the year before switching to natalizumab or fingolimod. Included patients received natalizumab or fingolimod for ≥3 months after the switch. RESULTS: Following 1:1 propensity score matching, 1000 natalizumab patients were matched to 1000 fingolimod patients. Mean (standard deviation) follow-up time was 3.02 (2.06) years after switching to natalizumab and 2.58 (1.64) years after switching to fingolimod. Natalizumab recipients had significantly lower annualized relapse rate (relative risk=0.66; 95% confidence interval [CI], 0.59-0.74), lower risk of first relapse (hazard ratio [HR]=0.69; 95% CI, 0.60-0.80), and higher confirmed disability improvement (HR=1.27; 95% CI, 1.03-1.57) than fingolimod recipients. No difference in confirmed disability worsening was observed. CONCLUSIONS: Patients with RRMS switching from BRACETD demonstrated better outcomes with natalizumab than with fingolimod.
CISSS de Chaudière Appalaches Lévis QC Canada
Department of Neurology Faculty of Medicine University of Debrecen Debrecen Hungary
Department of Neurology Monash University Melbourne VIC Australia
Department of Neuroscience Imaging and Clinical Sciences University G d'Annunzio Chieti Italy
Division of Neurology Department of Medicine Amiri Hospital Sharq Kuwait
Dokuz Eylul University Konak Izmir Turkey
Hôpital Notre Dame Montreal QC Canada and CHUM and Université de Montréal Montreal QC Canada
KTU Medical Faculty Farabi Hospital Trabzon Turkey
Medical Faculty 19 Mayis University Samsun Turkey
Neurosciences Unit Department of Medicine and Surgery University of Parma Parma Italy